Testosterone replacement therapy (TRT) clinics face added compliance requirements because testosterone is a Schedule III controlled substance under federal law. Clinics must address Drug Enforcement Administration (DEA) registration, controlled-substance prescribing, provider scope, physician oversight, laboratory monitoring, and dosing protocols. The goal is to make sure the full prescribing and monitoring process meets both federal and state requirements.
Key Takeaways
- Testosterone is a Schedule III controlled substance, adding federal prescribing and registration requirements to the TRT clinic’s compliance structure. (Jump to Section)
- Each practitioner prescribing controlled substances generally needs appropriate DEA registration or a valid exemption in addition to state authority. (Jump to Section)
- Testosterone, hematocrit, prostate risk, treatment response, and adverse effects should be addressed through an appropriate monitoring protocol. (Jump to Section)
- Telehealth TRT clinics must also account for current federal telemedicine rules for controlled-substance prescribing. (Jump to Section)
- State requirements can impose additional prescribing, physician collaboration, monitoring, and Prescription Drug Monitoring Program obligations. (Jump to Section)
Why TRT Clinics Face Extra Regulatory Scrutiny
A TRT practice does not operate under the same compliance framework as a clinic that only provides non-controlled wellness treatments.
The DEA currently classifies testosterone as a Schedule III controlled substance. Schedule III substances have a lower abuse potential than Schedule I or Schedule II drugs but remain subject to the federal Controlled Substances Act and related prescribing requirements.
That status affects several parts of a TRT practice:
- Prescriber Authority: The clinician issuing testosterone prescriptions must have the state authority required to prescribe controlled substances.
- DEA Registration: A practitioner prescribing testosterone generally must hold appropriate DEA registration unless a recognized exemption applies.
- Prescription Controls: Testosterone prescriptions must comply with federal controlled-substance requirements as well as state prescribing laws.
- Electronic Prescribing: Practices using Electronic Prescriptions for Controlled Substances (EPCS) must follow applicable authentication and access-control requirements.
- Documentation: The clinical record should support a legitimate medical purpose for treatment and show how the diagnosis and treatment plan were established.
- Monitoring: The practice needs a defined process for evaluating treatment response, laboratory findings, adverse effects, and continued appropriateness of therapy.
- State Requirements: State medical and nursing boards may impose additional requirements beyond federal controlled-substance rules.
The controlled-substance classification does not mean testosterone cannot be prescribed appropriately.
It means the clinic needs a more deliberate prescribing and oversight system.
What a Medical Director Should Oversee in a TRT Clinic
The medical director should understand the clinic’s full testosterone workflow rather than appearing only on a contract.
The exact responsibilities depend on state law, provider types, and the clinic structure.
Oversight may include:
- Clinical Protocols: Establish criteria for evaluating patients, diagnosing testosterone deficiency, initiating treatment, adjusting doses, and monitoring therapy.
- Provider Scope: Confirm which clinicians may evaluate patients and prescribe testosterone under applicable state law.
- Controlled-Substance Processes: Make sure practitioners involved in prescribing have the required state authority and DEA registration.
- Laboratory Standards: Define which laboratory results should be obtained before treatment and what monitoring occurs after therapy begins.
- Dosing Parameters: Establish how dose adjustments are made based on symptoms, testosterone concentrations, laboratory findings, and adverse effects.
- Chart Review: Review records at the cadence required by state law, the physician agreement, or the clinic’s internal quality process.
- Clinical Consultation: Provide a clear pathway when another clinician needs physician input about an unusual result, contraindication, complication, or dosing question.
- Escalation: Define when treatment should be held, discontinued, or referred for additional medical evaluation.
A physician’s responsibilities should also match what occurs in practice.
Written oversight that is never actually performed creates a different compliance problem.
Opening or expanding a TRT clinic?
Build physician oversight around controlled-substance prescribing.
Controlled Substance Prescribing and DEA Considerations
A medical director’s DEA registration does not automatically give every clinician in the practice authority to prescribe testosterone.
The DEA states that, unless an exemption applies, every practitioner who dispenses controlled substances in Schedules II through V must be registered. Federal law defines dispensing to include both prescribing and administering controlled substances.
This can include physicians and appropriately authorized mid-level practitioners such as nurse practitioners (NPs) and physician assistants (PAs).
The DEA also makes clear that federal registration depends on state authority. A practitioner must first have the state authorization necessary to handle controlled substances in the jurisdiction where they practice.
For a TRT clinic, verify:
- State Prescribing Authority: Confirm that each prescribing clinician may prescribe testosterone under their professional license.
- DEA Registration: Verify that each practitioner who requires individual registration has a current DEA registration covering Schedule III substances.
- State Controlled-Substance Registration: Some jurisdictions require a separate state registration before or alongside DEA registration.
- Practice Location: Determine whether the practitioner’s registration correctly covers the relevant place of professional practice.
- Multi-State Practice: Do not assume one DEA registration creates controlled-substance authority nationwide.
- Electronic Prescribing Access: Confirm that only properly authorized practitioners have access to sign controlled-substance prescriptions electronically.
DEA guidance states that a federal registration based on one state’s authority does not itself authorize controlled-substance prescribing in another state. Practitioners operating across states may need separate registrations based on where professional practice is established.
The Prescribing Clinician Matters More Than the Medical Director’s DEA Number
TRT clinics sometimes focus on whether the medical director has DEA registration.
That is only part of the analysis.
If another clinician is actually issuing the testosterone prescription, the clinic must confirm that that practitioner has the authority and registration required for the prescription.
For example, an NP authorized by state law to prescribe controlled substances may obtain their own DEA registration. DEA specifically recognizes nurse practitioners as potential mid-level practitioners when state law authorizes them to dispense controlled substances.
The medical director’s role does not substitute for the prescribing clinician’s required credentials.
Diagnosis Should Come Before the Prescription
A TRT protocol should establish how testosterone deficiency is diagnosed before controlled-substance treatment begins.
The Endocrine Society currently recommends diagnosing hypogonadism only when a patient has signs or symptoms consistent with testosterone deficiency and consistently low serum testosterone concentrations. It also recommends confirming the diagnosis with a repeat morning fasting total testosterone measurement.
In July 2026, the Endocrine Society reiterated that symptoms alone are not enough to diagnose hypogonadism. It emphasized the need for an accurate clinical diagnosis supported by consistently low testosterone measurements.
A clinic protocol may therefore address:
- Symptoms and History: Document clinical findings that support evaluation for testosterone deficiency.
- Initial Testosterone Testing: Obtain an appropriate testosterone measurement before treatment.
- Confirmatory Testing: Repeat testing when clinically indicated to confirm consistently low levels.
- Underlying Cause: Evaluate whether additional testing is needed to distinguish primary from secondary hypogonadism.
- Contraindications: Screen for conditions that may make testosterone treatment inappropriate or require further evaluation.
- Fertility Goals: Discuss the patient’s reproductive plans because exogenous testosterone can affect fertility.
The medical director should make sure the practice is treating an established clinical condition rather than relying only on symptoms or patient requests.
Lab Monitoring and Dosing Oversight
TRT monitoring should not consist of checking testosterone levels alone.
A structured protocol should evaluate whether treatment is effective, whether laboratory abnormalities are developing, and whether the patient remains an appropriate candidate for therapy.
Testosterone Levels
Testosterone concentrations help confirm the initial diagnosis and evaluate treatment after therapy begins.
The protocol should define when testing occurs and how results influence dosing rather than allowing dose changes to be based only on symptoms.
Hematocrit
Hematocrit deserves particular attention because testosterone therapy can increase red blood cell production.
The Endocrine Society identifies elevated hematocrit as a condition that should be considered before starting treatment. Its guideline also emphasizes continued monitoring after treatment begins.
The clinic should establish:
- Baseline hematocrit assessment;
- Follow-up testing;
- Thresholds that require additional evaluation;
- Dose-adjustment or treatment-hold procedures; and
- Referral pathways when abnormal findings persist.
Prostate-Specific Antigen and Prostate Risk
Prostate monitoring should be based on the patient’s age, risk factors, clinical circumstances, and applicable guideline recommendations.
The Endocrine Society recommends discussing prostate cancer risk and monitoring with appropriate patients before therapy. For patients who choose monitoring, prostate risk should be assessed before starting treatment and again after treatment begins.
The guideline also identifies circumstances in which a urological consultation should be considered during treatment, including certain increases in Prostate-Specific Antigen (PSA) levels or other concerning findings.
That does not mean the exact same PSA schedule applies to every patient.
The protocol should account for age, baseline risk, symptoms, and current clinical guidance.
Treatment Response and Adverse Effects
Laboratory monitoring is only one part of TRT follow-up.
The Endocrine Society recommends evaluating patients after therapy begins to assess treatment response, adverse effects, and adherence.
The medical director can help establish what clinicians should evaluate at follow-up visits and when treatment requires reconsideration.
Dosing Should Follow a Defined Clinical Process
Testosterone dosing should not be adjusted casually because a patient wants a higher level or reports that the medication “wears off.”
The clinic needs a reproducible method for dose management.
A TRT dosing protocol may address:
- Starting Dose: Define how the initial dose is selected based on the formulation and patient factors.
- Timing of Laboratory Testing: Specify when testosterone should be measured relative to the prescribed formulation.
- Dose Adjustments: Identify what clinical and laboratory information should support an increase or decrease.
- Adverse Effects: Establish when laboratory or clinical findings require dose reduction, treatment interruption, or additional evaluation.
- Formulation Changes: Define how patients are transitioned between injections, gels, patches, pellets, or other approved formulations when applicable.
- Missed Doses: Give clinicians and patients a consistent process for interruptions in treatment.
- Follow-Up: Establish how frequently the patient should be reassessed based on clinical needs and current guidance.
Protocols should support individualized care without turning dosing into an informal process.
Controlled-Substance Documentation Needs to Support the Prescription
A prescription for a controlled substance must be issued for a legitimate medical purpose by an authorized practitioner acting in the usual course of professional practice.
That makes documentation particularly important in a TRT clinic.
The patient record should support:
- Reason for Evaluation: Document the symptoms or clinical findings that prompted assessment.
- Diagnostic Testing: Maintain relevant testosterone and other laboratory results.
- Clinical Assessment: Record the clinician’s diagnosis and rationale for treatment.
- Treatment Discussion: Document important benefits, risks, alternatives, and patient counseling.
- Prescription Details: Record formulation, dose, frequency, and changes over time.
- Monitoring: Track laboratory findings, symptoms, adverse effects, and treatment response.
- Follow-Up: Document why treatment remains appropriate at subsequent visits.
- Escalation: Record referrals or additional evaluation when abnormal findings require further attention.
Documentation should tell the clinical story behind the prescription.
It should not simply show that testosterone was ordered.
Need physician oversight for testosterone prescribing?
Match your TRT model with the right physician.
Telehealth TRT Adds Another Compliance Layer
TRT clinics operating through telehealth need to consider both controlled-substance rules and telemedicine requirements.
As of September 2026, the DEA and the U.S. Department of Health and Human Services (HHS) have extended certain federal telemedicine flexibilities for prescribing controlled medications through December 31, 2026. Under those temporary rules, DEA-registered practitioners may prescribe Schedule II through V controlled medications through qualifying audio-video telemedicine encounters without first conducting an in-person evaluation, provided all other federal and state requirements are satisfied.
That temporary federal flexibility should not be interpreted as permission to prescribe testosterone anywhere in the country without additional review.
A telehealth TRT clinic should confirm:
- Patient Location: Determine where the patient is physically located during the encounter.
- Prescriber Licensure: Confirm that the practitioner may legally practice and prescribe in that state.
- Controlled-Substance Authority: Verify the practitioner’s state and federal authority for testosterone prescribing.
- DEA Registration: Make sure registration requirements are satisfied for the practitioner’s practice structure and locations.
- State Telehealth Rules: Review any state-specific in-person evaluation, consent, prescribing, or follow-up requirements.
- Future Federal Changes: Track what replaces or extends the current temporary DEA rules after December 31, 2026.
This is an area where the compliance framework can change quickly.
TRT telehealth practices should not build a permanent prescribing model around a temporary federal flexibility without monitoring regulatory developments.
Prescription Drug Monitoring Programs May Apply
Federal DEA registration is only one part of controlled-substance oversight.
States also operate Prescription Drug Monitoring Programs (PDMPs), and requirements for checking those databases vary.
A TRT practice should determine:
- Whether testosterone prescriptions must be reported;
- When the prescribing clinician must query the state PDMP;
- How often the database must be checked;
- What documentation should appear in the patient’s chart; and
- Whether exceptions apply.
The medical director should make sure the clinic’s prescribing protocol reflects the requirements of each state where testosterone is prescribed.
A generic nationwide policy may not be enough for a multi-state TRT practice.
State-by-State Requirements for TRT Clinics
Federal controlled-substance law creates a baseline, but state law determines much of the day-to-day clinical structure.
States can separately regulate:
- Who May Prescribe: Physician, nurse practitioner, and physician assistant controlled-substance authority varies.
- Physician Collaboration: Some practitioners may need a collaborating, supervising, or delegating physician.
- Controlled-Substance Registration: A state credential may be required in addition to DEA registration.
- Prescription Drug Monitoring Programs: Query and documentation requirements vary.
- Telehealth: States may impose additional rules on remote controlled-substance prescribing.
- Chart Review: Physician review requirements may apply to certain provider relationships.
- Practice Ownership: Corporate Practice of Medicine rules can affect who owns or controls the clinic.
- Laboratory and Follow-Up Requirements: State boards may impose standards beyond general federal controlled-substance rules.
- Medical Director Duties: Certain facilities or business models may require specific physician responsibilities.
A clinic should therefore review the state where it operates and, for telehealth, every state where patients will receive care.
One compliant setup should not automatically be copied into another jurisdiction.
TRT Clinic Compliance Checklist
Before prescribing testosterone, review the full clinic structure.
Compliance Question | Confirmed | Needs Review |
|---|---|---|
Testosterone’s Schedule III status addressed in clinic policies | ☐ | ☐ |
Prescribers have appropriate state authority | ☐ | ☐ |
Required DEA registrations are active | ☐ | ☐ |
State controlled-substance registrations are current | ☐ | ☐ |
Physician collaboration requirement has been confirmed | ☐ | ☐ |
Medical director agreement is current where applicable | ☐ | ☐ |
Diagnostic criteria are documented | ☐ | ☐ |
Repeat testosterone testing process is established | ☐ | ☐ |
Baseline hematocrit process is established | ☐ | ☐ |
Follow-up hematocrit monitoring is defined | ☐ | ☐ |
Prostate risk and PSA monitoring process is clinically appropriate | ☐ | ☐ |
Dose-adjustment protocol is documented | ☐ | ☐ |
Adverse-effect and escalation protocols are established | ☐ | ☐ |
Prescription Drug Monitoring Program requirements are addressed | ☐ | ☐ |
Electronic controlled-substance prescribing access is controlled | ☐ | ☐ |
Telehealth prescribing rules are reviewed where applicable | ☐ | ☐ |
Chart review process is established where required | ☐ | ☐ |
Patient follow-up process is documented | ☐ | ☐ |
A “Needs Review” result does not necessarily mean the clinic is operating unlawfully.
It means the clinic should resolve the issue before assuming its TRT prescribing structure is complete.
What to Look for in a TRT Medical Director
TRT oversight benefits from a physician who understands both hormone management and controlled-substance compliance.
Look for:
- Appropriate State Licensure: The physician should hold the licenses needed for the intended oversight relationship.
- TRT Experience: Familiarity with testosterone diagnosis, dosing, monitoring, contraindications, and complications improves clinical oversight.
- Controlled-Substance Knowledge: The physician should understand DEA requirements and the state rules relevant to testosterone prescribing.
- Laboratory Oversight: The medical director should be comfortable reviewing testosterone concentrations, hematocrit, prostate-related findings, and other clinically indicated results.
- Delegation Experience: If NPs, physician assistants, or other clinicians are involved, the physician should understand applicable collaboration and delegation rules.
- Telehealth Experience: Virtual TRT practices benefit from a physician who understands controlled-substance prescribing across telehealth workflows.
- Availability: The clinic needs a defined way to obtain physician consultation when laboratory results or clinical findings fall outside routine protocols.
- Chart Review Capacity: The physician should be able to perform required or agreed chart review consistently.
The right physician should strengthen the clinical system rather than simply satisfy a contractual requirement.
How Medical Director Co. Places TRT Clinic Medical Directors
Medical Director Co. matches clinics with licensed physicians based on state, specialty, and practice needs. For TRT practices, the physician relationship can be structured around hormone therapy, prescribing, clinical protocols, chart review, and ongoing oversight.
Medical Director Co. also supports state-specific agreements and compliance setup for practices where physician involvement is required. Current plans start at $799 per month, with physician matching available within 24 hours.
Need a medical director for your TRT clinic?
Get matched based on your state and services.
FAQs
Does a TRT clinic need a medical director?
A TRT clinic may need a medical director or another formal physician relationship depending on state law, provider type, ownership structure, and who prescribes testosterone. Testosterone’s controlled-substance status also creates federal requirements that apply separately from state medical director rules.
Is testosterone a controlled substance that requires special oversight?
Testosterone is classified by the Drug Enforcement Administration as a Schedule III controlled substance. Prescribing therefore must comply with controlled-substance requirements in addition to applicable medical, nursing, and state prescribing laws.
Does the medical director need a DEA registration?
A physician who prescribes, administers, or otherwise dispenses controlled substances generally needs appropriate Drug Enforcement Administration registration unless an exemption applies. If another practitioner actually prescribes testosterone, that clinician must also have the authority and registration required for their role.
Can a nurse practitioner prescribe testosterone?
A nurse practitioner may prescribe testosterone when state law authorizes the NP to prescribe Schedule III controlled substances and applicable federal requirements are satisfied. The DEA recognizes qualifying nurse practitioners as mid-level practitioners when the state permits them to dispense controlled substances.
What lab monitoring should a TRT medical director require?
Monitoring should include appropriate testosterone testing and assessment for treatment response and adverse effects. Hematocrit and prostate-related monitoring, including Prostate-Specific Antigen when clinically appropriate, should be incorporated according to patient characteristics and current clinical guidance.
Does every TRT patient need a PSA test?
The same prostate monitoring approach does not apply automatically to every patient. Age, baseline risk, symptoms, clinical history, shared decision-making, and current screening guidance should determine when Prostate-Specific Antigen testing or additional prostate evaluation is appropriate.
Can a TRT clinic prescribe testosterone through telehealth?
Federal temporary telemedicine flexibilities currently allow qualifying DEA-registered practitioners to prescribe controlled medications through eligible telemedicine encounters without a prior in-person examination under specified conditions. Those flexibilities currently run through December 31, 2026, and state law must still be followed.
Can the whole clinic use the medical director’s DEA number?
A medical director’s registration should not be treated as blanket prescribing authority for every practitioner in the clinic. Each person prescribing controlled substances must have the authority and registration or exemption applicable to that individual and practice arrangement.
How much does a medical director cost for a TRT clinic?
Medical Director Co. currently offers physician oversight plans starting at $799 per month. The exact arrangement depends on the state, provider structure, and services the TRT practice needs.
How quickly can I get a medical director for my TRT clinic?
Medical Director Co. currently offers physician matching within 24 hours for qualifying practices. The physician should be matched to the clinic’s state, clinical model, and oversight needs.
Controlled-Substance Oversight Should Be Built Into the TRT Model
Testosterone’s Schedule III status raises the compliance bar because TRT clinics must address controlled-substance authority, DEA registration, prescribing practices, clinical monitoring, and state-specific requirements. Physician oversight should support the entire treatment process, from diagnosis and dosing to laboratory review and clinical escalation.
Medical Director Co. can match TRT clinics with physicians who fit their state, services, and ongoing oversight needs.
Build your TRT clinic around compliant physician oversight.
Get matched with the right medical director.
Bolton M. Harris, J.D., is a seasoned attorney with a formidable background in criminal law and a focus on healthcare law and compliance. As the in-house legal counsel at Medical Director Co., Harris brings a unique blend of prosecutorial experience and regulatory expertise to support healthcare professionals across Texas. Her career spans roles as a prosecutor in multiple counties and now as a trusted advisor on the legal intricacies of medical practice operations.
Education & Early Career
Bolton Harris completed her undergraduate studies at Southern Methodist University (SMU) in 2013. During her time at SMU, she was not only a dedicated student but also a competitive athlete on the university’s women’s swimming team. She went on to earn her Juris Doctor from Texas A&M University School of Law in 2016 and became a member of the Texas Bar that same year. Armed with a strong academic foundation and discipline honed as a student-athlete, Harris embarked on a career in criminal law immediately after law school.
Prosecutorial Experience in Texas
Bolton Harris began her legal career in public service as a criminal prosecutor. She served as an Assistant District Attorney in multiple jurisdictions, where she quickly rose through the ranks and handled a broad spectrum of cases. Some highlights of her prosecutorial career include:
- Assistant District Attorney, Dallas County, Texas: Prosecuted a high volume of criminal cases in one of the state’s busiest DA offices, gaining extensive trial experience in both misdemeanor and felony courts.
- Assistant District Attorney, Ellis County, Texas: Continued to hone her courtroom advocacy skills, known for meticulous case preparation and a tenacious pursuit of justice on behalf of the community.
- Assistant District Attorney, Navarro County, Texas: Broadened her legal expertise by handling diverse criminal matters in a smaller county, working closely with law enforcement and community leaders to uphold the law.
Through these roles, Harris built a reputation for being a tough but fair advocate. She brought numerous cases to trial and developed an in-depth understanding of the criminal justice system. This distinguished prosecutorial background laid a strong foundation for the next phase of her career in the private sector.
Healthcare Law & Compliance at Medical Director Co.
After her tenure as a prosecutor, Harris shifted her focus to healthcare law, applying her legal acumen to the medical field. She recognized that the same attention to detail and tenacity that served her in criminal law could benefit healthcare providers navigating complex regulations. Embracing this new direction, Harris became well-versed in the intricate laws governing medical practices – from licensing requirements to patient safety and privacy standards – and is passionate about helping practitioners stay compliant.
In her current role as the in-house attorney for Medical Director Co., Bolton Harris oversees all legal and compliance matters for the organization and its clients. Medical Director Co. is a nurse-owned firm that connects nurse practitioners (NPs), physician assistants (PAs), and registered nurses with qualified medical directors and collaborating physicians, offering fast placements and comprehensive compliance support for healthcare practices. Harris ensures that each of these partnerships and clinical ventures adheres to all applicable state and federal laws. She is responsible for drafting and reviewing collaborative practice agreements, advising on regulatory requirements, and providing ongoing legal counsel as clients establish and grow their clinics. Drawing on her prosecutorial eye for risk management, Harris proactively identifies potential legal issues and addresses them before they escalate, giving healthcare professionals peace of mind.
Bolton M. Harris’s multifaceted expertise – spanning high-stakes courtroom litigation to detailed healthcare compliance – makes her a formidable legal ally. Whether advocating in front of a jury or guiding a medical practice through regulatory hurdles, she remains committed to the highest standards of the legal profession. Her blend of courtroom-tested skill and healthcare law knowledge ensures that clients of Medical Director Co. receive elite-level counsel and steadfast protection in an ever-evolving legal landscape.
